Evidence map›Paper›PMID 35497007›Full record

ArticleRSC advances2022

Construction of multi-substituted pyrazoles

Mei-Mei Li, Hui Huang, Wanrong Tian, Yiru Pu, Chaozheng Zhang, Jirui Yang, Qing Ren, Feiyan Tao, Yun Deng, Jun Lu

Open access · goldAbstract read
In one paragraph

Article in RSC advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Mei-Mei LiState Key Laboratory of Southwestern Chinese Medicine Resources, School of Pharmacy, Chengdu University of Traditional Chinese Medicine Chengdu 611137 China ljaaa111@163.com dengyun@cdutcm.edu.cn taofeiyan@163.com.ORCID https://orcid.org/0000-0001-5492-3263
Hui HuangState Key Laboratory of Southwestern Chinese Medicine Resources, School of Pharmacy, Chengdu University of Traditional Chinese Medicine Chengdu 611137 China ljaaa111@163.com dengyun@cdutcm.edu.cn taofeiyan@163.com.
Wanrong TianState Key Laboratory of Southwestern Chinese Medicine Resources, School of Pharmacy, Chengdu University of Traditional Chinese Medicine Chengdu 611137 China ljaaa111@163.com dengyun@cdutcm.edu.cn taofeiyan@163.com.
Yiru PuState Key Laboratory of Southwestern Chinese Medicine Resources, School of Pharmacy, Chengdu University of Traditional Chinese Medicine Chengdu 611137 China ljaaa111@163.com dengyun@cdutcm.edu.cn taofeiyan@163.com.
Chaozheng ZhangState Key Laboratory of Southwestern Chinese Medicine Resources, School of Pharmacy, Chengdu University of Traditional Chinese Medicine Chengdu 611137 China ljaaa111@163.com dengyun@cdutcm.edu.cn taofeiyan@163.com.
Jirui YangState Key Laboratory of Southwestern Chinese Medicine Resources, School of Pharmacy, Chengdu University of Traditional Chinese Medicine Chengdu 611137 China ljaaa111@163.com dengyun@cdutcm.edu.cn taofeiyan@163.com.
Qing RenSchool of Chinese Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong Hong Kong SAR 999077 China.ORCID https://orcid.org/0000-0002-8802-4810
Feiyan TaoResearch and Development Centre, China Tobacco Sichuan Industrial Co., Ltd Chengdu 610066 China.
Yun DengState Key Laboratory of Southwestern Chinese Medicine Resources, School of Pharmacy, Chengdu University of Traditional Chinese Medicine Chengdu 611137 China ljaaa111@163.com dengyun@cdutcm.edu.cn taofeiyan@163.com.
Jun LuState Key Laboratory of Southwestern Chinese Medicine Resources, School of Pharmacy, Chengdu University of Traditional Chinese Medicine Chengdu 611137 China ljaaa111@163.com dengyun@cdutcm.edu.cn taofeiyan@163.com.ORCID https://orcid.org/0000-0003-1625-8682
Chengdu University of Traditional Chinese Medicine · CNChina Tobacco · CNChinese University of Hong Kong · HKHong Kong Baptist University · HK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A highly efficient potassium carbonate-mediated [3 + 2] cycloaddition reaction of hydrazonoyl chlorides with cinnamic aldehydes to furnish multi-substituted pyrazoles under nontoxic and mild conditions has been developed. A plausible stepwise cycloaddition reaction mechanism is proposed. This protocol featured broad substrate coverage, good functional group tolerance, wide scalability, and operational simplicity, as well as conveniently constructed pyrazole scaffolds.

Identifiers

PMID35497007
PMCPMC9052213
OpenAlexW4225327819

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.